Presentation on theme: "The Organic Chemistry of Drug Design and Drug Action"— Presentation transcript:
1The Organic Chemistry of Drug Design and Drug Action Chapter 2Lead Discovery and Lead Modification
2Lead Discovery Approaches 1. Random screening - only approach before 1935; screen every compound you have; still a useful approach; streptomycin and tetracyclines identified in this way2. Nonrandom (or Targeted or Focused) screening - only screen compounds related to active compounds3. Drug metabolism studies - metabolites produced are screened for the same or other activities4. Clinical observations - new activities found in clinical trials; Dramamine tested as antihistamine (allergy) - found to relieve motion sickness; Viagra tested as antihypertensive - found to treat erectile dysfunction
3Lead Discovery Approaches (cont’d) 5. Rational approaches - identify causes for disease states:imbalance of chemicals in the bodyinvasion of foreign organismsaberrant cell growthIdentify biological systems involved in disease states; use natural receptor ligand or enzyme substrate as the lead; a known drug also can be used as a lead
4Rational Drug DesignChemical imbalances - antagonism or agonism of a receptor; enzyme inhibitionForeign organism and aberrant cell growth - enzyme inhibition; DNA interaction
5Dopamine as a lead compound Figure 2.1 Depiction of dopamine (DA) in its role as a neurotransmitter. DA is released by a neuron prior to interacting with dopamine receptors (D1–D5) on the surface of another nearby neuron. Also shown is the dopamine transporter, which terminates the action of dopamine by transporting the released neurotransmitter from the synaptic cleft back into the presynaptic neuron. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Drug Discovery (Kreek, M. J.; LaForge, K. S.; Butelman, E. Pharmacotherapy of addictions. Nat. Rev. Drug Discov. 2002, 1, 710–726) Copyright 2002.
11Enzyme substrates as lead compounds Physostigmine
12Kinases as targets—ATP is the lead compound Scheme 2.1 Reaction catalyzed by the kinase class of enzymes. Kinases catalyze the transfer of the terminal phosphate group of ATP or related molecules acceptor to the group of a substrate, in this case, an alcohol (ROH).
13Other and repurposed ligands as lead compounds AIDS -> antihistamineAntihypertensive -> Parkinson’sAntidepressant -> back pain
17Natural products seem to provide greater structural diversity than combinatorial chemistry. Natural products that are biologically active in assays generally have drug-like properties.Construction of chemical libraries based on natural product hits is a good compromise.
18Solid-Phase Synthesis of a Natural Product-like Combinatorial Library Library based on the 2,2-dimethylbenzopyran scaffold, a privileged structure.
19Solid-phase synthesis is used to make libraries of compounds Scheme 2.2 Solid-phase synthesis of a library of 7-hydroxybenzodiazepines
20Solid phase synthesis of a library Scheme 2.3 Solid-phase synthesis of a library of 4-alkoxyproline derivatives
21Combinatorial Chemistry Synthesis or biosynthesis of chemical libraries of molecules for lead discovery or lead modificationLibraries prepared in a systematic and repetitive way by covalent assembly of building blocks to give diversity within a common scaffold.Synthesis carried out on a solid support (polymer resin).Isolation and purification of product of each step done by filtration and washing. Everything not attached to polymer is washed away, which allows use of excess reagents.
22Alternatives: Carry out reactions in solution with excess reagents, which are scavenged with a polymer-bound scavenger. Filtration removes excess reagents bound to polymer.Or, use polymer-bound reagents.Main differences among various methods of combinatorial library synthesis:1. Solid support used2. Methods for assembling the building blocks3. The state (immobilized or in solution) in which libraries are screened4. Manner in which structures of active compounds are determined (encoding methods)
23If the # of building blocks varies in each step, then N = bcd... # synthetic stepsN = bx (Eq. 2.1)# compounds in library# building blocks in each stepIf the # of building blocks varies in each step, then N = bcd...For example, consider a 4-step synthesis. If 25 different reactants (building blocks) are used in the first two steps, 20 in step three, and 15 in step four, there would be 25 25 20 15 = 187,500 different compounds (from only 85 different building blocks).
24Peptide Libraries Split synthesis Also called mix and split or split and pool methodMost common lead discovery approach for large libraries ( compounds), assayed as library mixtures.Produces a collection of polymer beads, each containing one library member ( pmol)A combinatorial library of all pentapeptides comprised of the 20 common amino acids: 205 = 3.2 106 peptides.For example, prepare a homogenous mixture of all tripeptides of His, Val, and Ser (33 = 27)
25Split Synthesis of All Tripeptides Containing His, Val, and Ser
26Split Synthesis of Most Active Hexapeptide for a Opioid Receptor A combinatorial library is prepared of pentapeptides (comprised of the 20 main amino acids) bound to the MBHA polystyrene resin (makes peptide amides when cleaved off of resin)Separate into 20 tubes, then add a different N-acetylamino acid to each tubeAssay the 20 combinatorial library mixtures (either still attached to bead or after cleavage)Set the N-terminal amino acid of most potent library constant
27If the most potent was the library with Ac-Arg at N-terminus, Set all to ArgVary 2nd amino acidNext 4 amino acids are a combinatorial libraryDetermine best residue at 2nd position, then repeat process for 3rd position.Continue until you get most potent N-acetyl hexapeptide amide (in this case, AcArg-Phe-Met-Trp-Met-Thr-NH2).
28Problems with Split Synthesis Approach Most potent analog may be less potent than what was observed in a previous iterationPeptide-peptide interactions may have been responsible for previous potency (some peptides removed in next step)Active compound may be a complex of more than one peptide (some peptides removed in next step)Conformation may be different with fewer peptides present
29Nonpeptide Libraries Problems with Assaying Multiple Compounds Together Many false negatives (active compound that does not produce a hit) and false positives (inactive compound that does produce a hit) observed.Therefore, single entity screens are used.Parallel synthesis - solid-phase reactions carried out to make individual compounds rapidly (and robotically)The library ( compounds) is made in parallel without combining tubes so each support has one compound attached.The goal is to get as much molecular diversity with as much functionality as possible.
30Solution phase synthesis of a library Scheme 2.4 Solution-phase synthesis of a library of furanose derivatives
31Libraries can be made in microtiter plates Figure 2.2 (A) Schematic of a typical 96-well microtiter plate. (Reprinted with permission from Custom Biogenic Systems (http://www.biomedicalmarketing.com/CBS/MicrotiterCRacks.html).) (B) Picture of a 96-well microtiter plate taken by Jeffrey M. Vinocur, 4/21/06, published on Wikipedia Commons (http://commons.wikimedia.org/wiki/File:Microtiter_plate.JPG)
32Libraries can be made in microtiter plates Figure 2.4 Image of 96-well filter plates. Reprinted with permission from Norgen Biotek Corp.
33Polymer-bound scavenger reagents can be used in synthesis Figure 2.3 Product of polymer-bound N-methylglucosamine with borate anion
34Another solid-phase scavenger Scheme 2.5 Use of a solid-phase scavenger in solution-phase synthesis. In this example, a polymer-bound isocyanate is used to scavenge excess primary or secondary amine from a solution by forming the corresponding polymer-bound urea.
35An antitumor drug discovered by combinatorial synthesis and high-throughput screening
36Advantages and problems in high throughput synthesis Solid-phase synthesis can make large numbers of compounds, but purification is problematic and quantities are small.Solution-phase synthesis makes smaller numbers of compounds, but larger quantities and easier purification.
37Properties that Influence Oral Bioavailability Lipinski’s Rule of 5 The “rule of 5” states that poor oral absorption and/or distribution are more likely when:The molecular weight is > 500The log P is > 5There are more than 5 H-bond donors (expressed as the sum of OH and NH groups)There are more than 10 H-bond acceptors (expressed as the sum of N and O atoms)It is highly likely (>90%) that compounds with two or more of these characteristics will have poor absorption properties. Antibiotics, antifungals, vitamins, and cardiac glycosides are the exception because they often have active transporters to carry them across membranes.
38Alternative to Lipinski’s Rule of Five Veber and co-workers Poor oral bioavailability found as a result of increased molecular flexibility (independent of molecular weight), as measured by:greater than 10 rotatable bondshigh polar surface area (> 140 Å2)total hydrogen bond count (> a total of 12 donors and acceptors)Both the number of rotatable bonds and hydrogen bond count tend to increase with molecular weight, which may explain Lipinski’s first rule.Reduced polar surface area was found to correlate better with an increased permeation rate than did lipophilicity.
39Privileged Structures and Drug-like Molecules Certain scaffolds are capable of binding to multiple receptor targetsAppropriate structural modifications can change the activityNOYRHC'Privileged structurebenzodiazepines(a) Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkel, K. A.; Springer, J. P.; Hirshfield, J. J. Med. Chem. 1988, 31, (b) Ariëns, E. J.; Beld, A. J.; Rodrigues de Miranda, J. F.; Simonis, A. M. in The Receptors: A Comprehensive Treatise; O'Brien, R. D., Ed.; Plenum Press: New York, 1979, p. 33. (b) Ariëns, E. J. Med. Res. Rev. 1987, 7, 367. (c) Patchett, A. A.; Nargund, R. P. Annu. Rep. Med. Chem. 2000, 35, 289. (d) Hajduk, P. J.; Bures, M.; Praestgaard, J.; Fesik, S. W. J. Med. Chem. 2000, 43, (e) Fecik, R. A.; Frank, K. E.; Gentry, E. J.; Menon, S. R.; Mitscher, L. A.; Telikepalli, Med. Res. Rev. 1998, 18, 149. (f) Horton, D. A.; Bourne, G. T.; Smythe, M. L. J. Computer-Aided Mol. Des. 2002, 16, 415. (g) Klabunde, T.; Hessler, B. Chembiochem. 2002, 3, 928. (h) Matter, H. Baringhaus, K.H.; Naumann, T.; Klabunde, T.; Pirard, B. Comb. Chem. High Throughput Screen. 2001, 4, 453. (i) Horton, D. A.; Bourne, G. T.; Smythe, M. L. Chem. Rev. 2003, 103, 893.
40Drug-likeness Only 32 scaffolds describe half of all known drugs.1 Average number of side chains per molecule is 4. If carbonyl is ignored, then 73% of the side chains in drugs are from top 20 most common side chains.2Drug-likeness may be an inherent property of some molecules.3Try these first.1 Bemis, G. W.; Murcko, M. A. J. Med. Chem. 1996, 39, 2887.2 Bemis, G. W.; Murcko, M. A. J. Med. Chem. 1999, 42, 5095.3 Ajay; Walters, W. P.; Murcko, M. A. J. Med. Chem. 1998, 41, 3314.
41Privileged structures Figure 2.5 Pairs of compounds containing a privileged structure (indole, dihydropyridine, or benzimidazole) and binding to diverse target classes
42Some groups should be avoided because of possible toxicity
43Sucralose is an alkyl halide, but was approved as a non-nutritive sweetener
44Many nondrug-like molecules show up as active in screens - false positives. Appear to bind to numerous receptors, but not at the site of the natural ligand (called promiscuous drugs)May be the result of aggregate formation
45Virtual screening can accelerate lead identification Scheme 2.6 The process of virtual screening to identify compounds that conform to a hypothesis specifying properties (that are discernible from a compound’s structure) that are required for activity
46Virtual screening databases are available Tripos LeadQuestMaybridgeAccelrys ACDZINC-a free database
47Virtual screening process Identify substructure linked to desired activitySearch database for molecules with active substructure2D search just matches the structure3D search can match molecular shape
48Substructure search problems Figure 2.6 Hypothetical example illustrating that substructure search (e.g., using pyridine as the search query) may not retrieve the most structurally similar compounds in a compound collection
49How to quantify similarity? T = N11/n-N00 = 7/18-4 = 0.50
50Computer-Based Methods of QSAR 3D-QSAR correlates diverse molecular structures and their biological function at a particular target.General approachassay a set of moleculesalign molecules according to some predetermined orientation rulescalculate a set of spatially dependent parameters for each molecule determined in the receptor spacederive a function relating each molecule’s spatial parameters to their biological propertyestablish self-consistency and predictability of the function
51Comparative Molecular Field Analysis (CoMFA) Molecule-receptor interactions are represented by steric and electrostatic fields exerted by each moleculeA series of active compounds are identified and 3-D structural models constructedThese structures are superimposed on one another and placed within a regular 3-D gridA probe atom placed at lattice points on grid where it is used to calculate steric and electrostatic potentials between itself and each superimposed structureA 3-D contour map is constructed to identify where lower or higher steric or electrostatic interactions increase binding
52A pharmacophore based on known ligands Figure 2.7 Example of a computer-generated pharmacophore model. From Laurini et al Bioorg. Med. Chem. Lett (Ref. 111)
53Molecular GraphicsUse of computers to display and manipulate molecular structures based on Fischer lock-and-key hypothesis.synonymous names for the methodStructure-based drug designComputer-assisted drug designComputer-assisted molecular designCommercial software, such as Sybyl (Tripos), Insight II (Molecular Simulations), and Gold (Cambridge Crystallographic Data Center), are used.Need a high-resolution (crystal or solution) structure of a receptor with a ligand bound. The ligand can be removed graphically to expose the receptor binding site.Other molecules are docked into the binding site.
54Haldol, a lead for HIV-1 protease inhibitors from docking
55From “hit” to lead Screening results in hits In HTS, need to identify and confirm structure of hitsIn virtual screening, need to perform assays to confirm activityA series of analogs may be preparedLigand efficiency = ΔG/N
57Comparison of ligand and fragments Ki1 μM40 mM19 mM10 mMBut structural studies show that the fragments do not bind in the same site
58SAR by NMR NMR approach to identify and optimize high-affinity ligands bound to proteins Figure 2.8 SAR by NMR methodologyScreen ~10 compounds at a time. Look for a 15N-chemical shift in the protein NMR indicating compound bound at that amino acid in the protein.Once lead is identified, make a focused library of analogs to optimize lead.Screen a 2nd library to find one that binds to a site near to where the first compound bound. Optimize the 2nd lead.Link the two compounds together - binding affinity is dramatically increased.
59Example of SAR by NMRInhibition of stromelysin, a matrix metalloprotease (degrades extracellular matrix components in tissue remodeling and in arthritis, osteoporosis, and cancer)Site 1Site 2LinkerKd = 17 mMKd = 20 MKd = 17 nMTook 6 months to identify Prior to this, no leads had been identified.
61SAR by NMR What’s Really Involved? To see a 15N chemical shift in NMR spectrum:1. Overexpress protein in microorganism grown on 15NH4Cl as sole N source to incorporate 15N in all amino acids2. Purify protein (need > 200 mg per spectrum)3. Determine 3D structure of protein by various NMR techniques (mass < 40 kDa)If structure can be determined, SAR by NMR can screen 1000 compounds a day.
62Generating a lead from fragments Figure 2.9 Ellman combinatorial methodology for lead generation with an unknown or impure protein
63SAR by MS High-throughput mass spectrometry-based screen A set of diverse compounds screened by mass spectrometry to identify those that bind to a receptorCompetition experiments determine compounds bound to different sites (ternary complex if bound to different sites; binary complex if at same site)For molecules bound to different sites, vary substituent size to determine which bind at adjacent sitesAttach the two molecules with a linker
64Substrate activity screening (SAS) Figure 2.10 Steps of SAS for identification of protease inhibitors
65Linking fragmentsFigure 2.11 Three approaches to linking fragments: (A) fragment evolution, (B) fragment linking, and (C) fragment self-assembly. Reprinted with permission from Macmillan Publishers Ltd: Nature Reviews Drug Discovery (Reese, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Fragment-based lead discovery. Nat. Rev. Drug Discov. 2004, 3, 660–672) Copyright 2004.
66Fragment evolutionFigure 2.12 Example of fragment-based lead discovery incorporating the fragment evolution approach followed by lead modification to an optimized compound. Ligand efficiencies help guide the overall process.
67Fragment self-assembly—click chemistry Figure 2.13 Example of fragment-based lead discovery incorporating the fragment self-assembly approach: click chemistry
68Leads for sleeping sickness Figure 2.14 (A) Structure of 2.51 complexed with 6-phosphogluconate dehydrogenase (6PGDH) determined by X-ray crystallography. (B) Structure of 2.53 complexed with 6PGDH predicted by computational docking. From Ruda, et al. Bioorg. Med. Chem. 2010, 18, 5056–5062.
69Fragment-based development of a urokinase-type plasminogen activator inhibitor Figure 2.15 Progression from mexiletin (2.55, identified by fragment-based screening) to a potent orally bioavailable uPA
70Lead OptimizationPharmacodynamics receptor interactions - structure of lead is similar to that of the natural receptor ligand or enzyme substratePharmacokinetics ADME - Absorption, Distribution, Metabolism, Excretion; depends on water solubility and lipid solubilityToxicity
71Identification of the Active Part of the Lead First consider pharmacodynamicsPharmacophore - the relevant groups on the compound that interact with the receptor and produce activityAuxophore - the rest of the molecule
72Some of the auxophoric groups interfere with binding of pharmacophoric groups and must be excised. Some of the auxophoric groups may neither bind to the receptor nor prevent the pharmacophoric groups from binding - these can be modified without effect on potency.Modification of these auxophoric groups may be used to correct ADME problems.
73One approach to determine which are pharmacophoric atoms, which are auxophoric atoms hindering binding, and which are auxophoric atoms that can be modified is to cut away pieces of the lead and measure the effect on potency.
74Example of Pharmacophore and Auxophore Identification Assume the well-known addictive analgesics below are the lead compounds. The darkened part is known to be the pharmacophore (you would not know that in a real-life example).All bind to the opioid receptorWhat happens if we excise the bridging O (shown above not in the pharmacophore)?
75Maybe additional conformational flexibility 3-4 times more potent than morphineNote: The structure is drawn to mimic that of morphine; it is not the lowest energy conformer.Maybe additional conformational flexibilityallows the molecule to bind more effectively.
76Next, remove half of the cyclohexene ring (also not in the pharmacophore). Less potent than morphine, but much lower addictive properties.about the same potency as morphine
77Removal of more rings Demerol Potency similar to morphine 10-12% the potency of morphine
78If every cut gives lower potency, either most of the molecule is in the pharmacophore or the cut causes a conformational change away from the bioactive conformation. Add groups to increase the pharmacophore.3200 times more potent than morphine
79Fentanyl and derivatives are the most potent opiates known Fentanyl and derivatives are the most potent opiates known. Is the ester group in carfentanil part of the pharmacophore?
80Functional Group Modification Antibacterial agent carbutamide (2.64, R = NH2) has an antidiabetic side effect.Replacement of NH2 by CH3 gives tolbutamide (2.64, R = CH3), which is an antidiabetic drug with no antibacterial activity.An obvious relationship exists between molecular structure and its activity.
81Antihypertensives Antihypertensive with diuretic activity Antihypertensive withoutdiuretic activity
82Structure-Activity Relationships (SARs) Crum-Brown and FraserExamined neuromuscular blocking effects of a variety of simple quaternary ammonium salts to determine if the quaternary amine in curare was the cause for its muscle paralytic properties.Conclusion: the physiological action is afunction of chemical constitution
83Curare alkaloidFigure 2.16 Structure of d-tubocurarine, a constituent of curare
84Structurally specific drugs (most drugs): Act at specific sites (receptor or enzyme)Activity/potency susceptible to small changes in structureStructurally nonspecific drugs:No specific site of actionSimilar activities with varied structures (various gaseous anesthetics, sedatives, antiseptics)
85Example of SAR Lead: sulfanilamide (R = H) Thousands of analogs synthesizedFrom clinical trials, various analogs shown to possess three different activities:AntimicrobialDiureticAntidiabetic
86SAR General Structure of Antimicrobial Agents R = SO2NHR, SO3HGroups must be paraMust be NH2 (or converted to NH2 in vivo)Replacement of benzene ring or added substituents decreases or abolishes activityR can be(but potency is reduced)R = SO2NR2 gives inactive compounds
88SAR Diuretics (2 types) hydrochlorothiazides R2 is an electrophilic grouphigh ceiling type(high level of diuresis)
89SAR for PaclitaxelPaclitaxel (2.72, Taxol) - anticancer drug
90SAR Conclusions Use of a molecular activity map- Figure 2.17Use of a molecular activity map-structural drawing of a lead annotated to show where structural changes affect activity or potency
91Structural Modifications Increase potency, therapeutic index and ADMEIncrease therapeutic index - measure of the ratio of the concentration of a drug that gives undesirable effects to that which gives desirable effectse.g., LD50 (lethal dose for 50% of the test animals)ED50 (effective dose to give maximum effect in 50% of test animals)Therefore, want LD50 to be large and ED50 to be small.The larger the therapeutic index, the greater the margin of safety.The more life threatening the disease, the lower is an acceptable therapeutic index.
92Chlorambucil, an antitumor drug Therapeutic index = 23
93Types of Structural Modifications Homologation - increasing compounds by a constant unit (e.g., CH2)Effect of carbon chain length on drug potencyFigure 2.18Pharmacokinetic explanation: Increasing chain length increases lipophilicity and ability to cross membranes; if too high lipophilicity, it remains in the membranePharmacodynamic explanation: Hydrophobic pocket increases binding with increasing length; too large and does not fit into hydrophobic pocket
94Branched chain groups are less lipophilic than straight chain groups. in throat lozengesBranched chain groups are less lipophilic than straight chain groups.
95More potent than the tertiary homolog Chain BranchingOften lowers potency and/or changes activity; interferes with receptor bindingMore potent than the tertiary homolog
96Phenothiazines All bind to different receptors 10-Aminoalkylphenothiazines (X = H)Promethazine-antispasmodic/antihistamineactivities predominatePromazine-greatly reduced antispasmodic/antihistamineActivities, greatly enhanced sedative/tranquilizing activitiesTrimepazine-reduced tranquilizing activityenhanced antipruritic (anti-itch) activity
97BioisosterismBioisosteres - substituents or groups with chemical or physical similarities that produce similar biological properties. Can attenuate toxicity, modify activity of lead, and/or alter pharmacokinetics of lead.
102Changes in Activity by Bioisosterism If the S in phenothiazine neuroleptic drugs (2.75) isreplaced by -CH=CH- or -CH2-CH2- bioisosteres, then dibenzazepine antidepressant drugs (2.76) result.
103Changes resulting from bioisosteric replacements: Size, shape, electronic distribution, lipid solubility, water solubility, pKa, chemical reactivity, hydrogen bondingEffects of bioisosteric replacement:1. Structural (size, shape, H-bonding are important)2. Receptor interactions (all but lipid/H2O solubility are important)3. Pharmacokinetics (lipophilicity, hydrophilicity, pKa, H-bonding are important)4. Metabolism (chemical reactivity is important)Bioisosteric replacements allow you to tinker with whichever parameters are necessary to increase potency or reduce toxicity.
104Bioisosterism allows modification of physicochemical parameters Multiple alterations may be necessary:If a bioisosteric modification for receptor binding decreases lipophilicity, you may have to modify a different part of the molecule with a lipophilic group.Where on the molecule do you go to make themodification?The auxophoric groups that do not interfere with binding.
106Ring-Chain Transformations Transformation of alkyl substituents into cyclic analogs, which generally does not affect potency.Ring-chain transformation can havepharmacokinetic effects, such as increasedlipophilicity or decreased metabolism.2.80 and 2.81 have equivalent tranquilizing effects2.82. and 2.83 have similar antipruritic activity2.84 has better antiemetic activity than 2.80
107Ring-chain transformations can affect toxicity nontoxic
108Peptidomimetics rapidly proteolyzed in GI tract and serum Peptides are important endogenous molecules - neurotransmitters, hormones, neuromodulatorsPeptide drugs - analgesics, antihypertensives, antitumor agentsPeptides generally do not make good drug candidatesrapidly proteolyzed in GI tract and serumpoorly bioavailablerapidly excretedbind to multiple receptorsPeptidomimetic - a compound that mimics or blocks the biological effect of a peptide, but without undesirable structural characteristics
109Use the peptide as a lead - modify to minimize undesirable pharmacokinetic properties Try to mimic structure of the peptide when it is bound to the target receptorReplace as much of the peptide backbone as possible with nonpeptide fragments - leave the pharmacophoric groupsInitially, retain conformational flexibility, but then refine to more conformationally-rigid analogs to hold groups in a bioactive conformation.
119Mechanism of peptide hydrolysis Figure 2.24 Hydrolysis of a peptide bond showing the tetrahedral intermediate arising from nucleophilic attack of water on the carbonyl group of the peptide bond. The hydroxyethylene isostere analog is designed to mimic the tetrahedral intermediate.
120Structure Modifications to Increase Oral Bioavailability ~ 75% of drug candidates do not go to clinical trials because of pharmacokinetic problemsLess than 10% of drug candidates in clinical trials go to market~ 40% of molecules that fail in clinical trials do so because of pharmacokinetic problemsTherefore, examine pharmacokinetic problems, such as oral bioavailability and plasma half life, as early as possible in the drug discovery process.
121Low water solubility (high lipophilicity) can be an important limiting factor for oral bioavailability.Highly lipophilic compounds are easily metabolized or bind to plasma proteins.Low lipophilicity leads to poor absorption (cannot cross membranes).Therefore, need to know lipophilicities of molecules and of substituents.Determination of lipophilicities of substituents by Corwin Hansch and co-workers is based on the Hammett equation for electronic effects.
122Electronic Effects The Hammett Equation Hammett’s postulate:Electronic effects (both inductive and resonance) of a set of substituents should be similar for different organic reactions.Therefore, assign values for the electronic effect of different substituents in a standard organic reaction, then use these values to estimate rates in a new reaction.
123Hammett Equation Standard system: benzoic acid derivatives Equilibrium ConstantsScheme 2.7As X becomes more e--withdrawing, the reaction to the right should be favored (increased Ka).
124Rate ConstantsScheme 2.8As X becomes more e--withdrawing, rate should increase because of transition state stabilization (lower activation energy).
125Linear Free-Energy Relationship Rates of hydrolysis of ethyl benzoatesnot for ortho substituents- steric/polar effectsDissociation constants of benzoic acids
126kKlog= logkoKoslope of lineko and Ko are rate and equilibrium constants, respectively, for the parent compound (X = H)KIf is defined as ,logKokthenlog=Hammett equationkoElectronic parameter (depends on electronic properties of substituent)the more e--withdrawing, more +the more e--donating, more -Reaction constant (depends on reaction conditions)carbocation intermediate, - slopecarbanion intermediate, + slopeH = 0.0
127Lipophilicity Effects: Hansch Equation Hansch thought there should be a linear free-energy relationship between lipophilicity and biological activity.Action of drug depends on 2 processes:1. drug has to get to site of action (pharmacokinetics)2. drug has to interact with site of action (pharmacodynamics)
128Fluid Mosaic Model of Membrane Drug must pass through various membranes to reach the site of action Figure 2.26lipid bilayerhydrophilic heads (OH, NH3+, sugars)Correlations noted earlier between lipid solubility and biological activitylipophilic tails (steroid and hydrocarbon chains)
130Measured Lipophilicities Model for transport of drug to site of action Ability of compound to partition between 1-octanol (simulates membrane) and water (simulates cytoplasm)Measure of lipophilicity: partition coefficient (P) between 1-octanol and water:[compound]1-octanolP =(Eq. 2.7)[compound]water (1-)degree of dissociation in H2O from ionization constants
131Relative potency of drug (log ) 1Relative potency of drug (log )Cconcentration of drug that produces the biological effect1log = -k(log P)2 + k(log P) + kCFor a compound more soluble in H2O than in 1-octanolP < 1; log P is -For a compound more soluble in 1-octanol than in H2OP > 1; log P is +The larger the P, the more interaction of the drug with membranes (more lipophilic)
132Parabolic Relationship Between Potency (log ) and log P 1Coptimum partition coefficient for biological activitylog P0 should be 2 to penentrate the CNSFigure 2.27 Effect of log P on biological response. P is the partition coefficient, and C is the oncentration of the compound required to produce a standard biological effect. Log Po is the optimal log P for biological activity.
133Ionization of compounds leads to greater water solubility than predicted from the neutral structure. For compounds that can ionize (COO-, NH3+, etc.) use log D - log of distribution coefficient.Ionization is a function of pKa of a compound and pH of the medium; therefore, must specify pH.log D is the log P of an ionizable compound at a particular pH.log D7.4 is the log P at pH 7.4
134Effect of pH on log D fully protonated amine decreased concentration of protonated amine
135Lipophilicity Substituent Constants p Derived the same as electronic substituent constants = log PX - log PH = logPXPHlog P for a compound with substituent Xlog P for a compound with no substituent
136 (like ) is additive and constitutive Multiple substituents exert lipophilicity equal to the sum of individual substituentsEffect depends on the molecule to which it is attachedAlkyl groups are least constitutiveCH3 ≈ 0.50By definition, H = 0Therefore, CH2 = CH3
141Example of Additivity of Constants Branching lowers log P or by 0 Example of Additivity of Constants Branching lowers log P or by 0.2/branchbranchinglog P2.83 = 2Ph + CH + OCH2 + CH2 + NMeOCH2 = log PCH3CH2OCH2CH3 - 2CH3 - CH2= (0.5) = -0.73NMe2 = log PPh(CH2)3NMe2 - Ph - 3CH2= (0.5) = -0.95log P2.83 = 2(2.13) (-0.73) (-0.95) - 0.2= 3.38branchingExperimental log P = 3.27
142Computerization of Log P Values Several software packages are available to calculate log P.However, log P values can vary by 2 or more units among software packages. values are constitutive - cannot account for all substituents on every scaffold.Measure log P for one member of a library, then see which software package comes closest to the experimental value.
143Effects of Ionization on Lipophilicity and Oral Bioavailability Amino acid residues in receptors are ionizedAsp/Glu -COOH pKaCys -SHTyrSer/Thr -OHHisLys -NHArgAt physiological pH (pH 7.4) each is partially ionized and partially neutral.pH = pKa –log [HA]/[A-]
144Ionization of a drug depends on pKa of groups and pH. Ionization has profound effect on lipophilicity (pharmacokinetics) and interaction with a receptor (pharmacodynamics).What if ionization of a drug is important for its binding to a receptor, but ionization may block its ability to cross membranes?Need to vary pKa to adjust equilibrium of ionized (bind to receptor) and neutral (cross membranes) form.Neutral form crosses membranes, then re-establishes equilibrium with ionized form on other side.
145Ionized molecules that did not cross the membrane re-establish equilibrium with the neutral form, which can cross the membrane.Drug metabolism and excretion prevent continual re-establishment of equilibrium.The pKa of most alkaloids that act as neuroleptics, local anesthetics, and barbituates have values between 6 and 8.At neutral pH there is a mixture of neutral and cationic forms.
147Sulfinpyrazone (R=CH2CH2SOCH3)has a pKa of 2.8 The uricosuric drug phenylbutazone has a pKa of 4.5 and is active as an anion.Scheme 2.10 Ionization equilibrium for phenylbutazoneThe pH of urine is ~ 4.8.Sulfinpyrazone (R=CH2CH2SOCH3)has a pKa of 2.8Therefore all in anionic form.20 times more potent than phenylbutazone
148Effect of ionization can be rationalized from pharmacokinetic or pharmacodynamic perspective. Pharmacokinetic - neutral form increases crossing of membranesPharmacodynamic - neutral form binds in a hydrophobic pocket in receptorThese can be differentiated using an isolated receptor (no membranes to cross so only pharmacodynamics) and whole cells or tissue (membranes to cross so pharmacokinetics and pharmacodynamics are important).
149Pyrimethamine is absorbed as the neutral molecule, but active as the protonated ion
150In a cell-free system (no membranes), the antibacterial activity of sulfamethoxazole is directly proportional to the degree of ionization (pharmacodynamics).Scheme 2.11 Ionization equilibrium for sulfamethoxazoleIn intact cells, where a drug must cross a membrane to get to the site of action, the antibacterial activity is proportional to its lipophilicity (neutral).
151Actual pKa Values pKa values depend on the microenvironment Molecular dynamics simulations indicate that the interior of proteins have dielectric constants about 2-3 (like benzene or dioxane); water has a high dielectric constant (78.5).COOH in a nonpolar environment - pKa higher because ionized form is destabilized.Asp-99 in 3-oxo-5-steroid isomerase is 9.5!Represents a change in equilibrium of 105 in favor of neutral form.
152COOH that forms a salt bridge - pKa lower Multiple COOH groups adjacent - pKa higher to avoid adjacent anionic groupsNH2 in a nonpolar environment - pKa lower to avoid cationic formNH2 in a salt bridge is stabilized - pKa higherMultiple basic groups adjacent - pKa lower to avoid adjacent cationic groupsLys amino group in acetoacetate decarboxylase has pKa 5.9 because adjacent residue is another Lys. Again about 105 change in equilibrium.
153Such large changes in pKa in microenvironment indicate that lead modification also should involve large pKa variances.Determine in vitro and in vivo effects with pKa changes.
155CNS drugs must cross the blood-brain barrier InactiveActiveActive
156Quantitative Structure-Activity Relationships Crum-Brown and Fraser predict a mathematical relationship would be found between structure and activityCorwin Hansch attempts to quantify effects of substituent modifications
157QSAR Basis for quantitative drug design: Biological properties are a function of the physicochemical parameters, e.g., solubility, lipophilicity, electronic effects, ionization, stereochemistry, etc. and constants should be important considerations in lead modification.Steric factors also should be important for receptor binding.
158Steric Effects: Taft Equation Taft defined a steric parameter EsReference reaction:XCH2CO2Me XCH2CO2H + MeOHH3O+Es (X = H) = 0CH3k0Es = log kXCH2Me - log kCH3CO2Me = logkXHancock: Ecs= Es =0.306(n-3) corrects for hyperconjugation
159regression coefficients potency Hansch Equation Correlation of Physicochemical Parameters (descriptors) with Biological ActivityHansch analysisBecause there are at least two considerations for drug activity, lipophilicity (to get drug to the site of action) and electronic factors (at the site of action), Hansch derived:1log = -k2 + k + + kCregression coefficientspotencyHansch Equation
160Hansch equation generalized: 1log = -a2 + b + + cEs + dS + eClipophilicity constantelectronic constantsteric constantother physico-chem. parameterspotencyLinear multiple regression analysisThe best least-squares fit of the dependent variable (biological activity) to a linear combination of independent variables (descriptors) is determined.
161Topliss Operational Schemes - Lead Optimization Nonmathematical, nonstatistical, noncomputerized use of Hansch principles.Consider benzenesulfonamide as lead (R = H)Vary and and determine effect on potency.This method requires an unfused benzene ring.
162Topliss Decision TreeBecause potency often increases with lipophilicity, first try a substituent with a + value (e.g., Cl; 4-Cl = 0.71, 4-Cl = 0.23).Three possible outcomes - more potent (M), equipotent (E), or less potent (L) than parent.If more potent, can be because of +, +, or both.Hold one constant and vary other:4-PhS = 2.32, 4-PhS = 0.18 would test lipophilicity4-CF3 = 0.88, 4- CF3 = 0.54 would test electron withdrawalIf 4-PhS compound is more potent than 4-Cl, increase lipophilicity more.
164If 4-Cl analog is equipotent with parent, may be a counterbalance of favorable + and unfavorable + or vice versa.Try 4-Me 4-Me = 0.56, 4-Me = or4-NO2 4- NO2 = -0.28, 4- NO2 = 0.78If 4-Cl analog is less potent than parent, there may be a steric problem at C-4 or need - and/or -.Try 3-Cl 3-Cl = 0.71, 3-Cl = 0.37
165Craig plot of σ and π values Figure 2.29 Craig plot of σ constants versus π values for aromatic substituents. This material is reproduced with the permission of John Wiley & Sons, Inc. From Craig, P. N. (1980) In "Burger’s Medicinal Chemistry," (M. E. Wolff, ed.), 4th ed., Part I, p Wiley, New York.
166Batch Selection Methods With Topliss operational scheme you need results from one compound before you know what to make next.Batchwise methods involve making a small group of preselected analogs and testing.Rank order the potencies, then compare with the rankings in Table 2.17.This table tells you which parameter is most important.E.g., if rank is 3,4-Cl2 > 4-Cl > H > 4-Me > 4-OMe, then is most important.
167Then consult Table 2.18 for other substituents with that parameter. Cannot extend this method without computation.
168Cluster Analysis Select one member from each cluster See which dominates
170Free-Wilson approach to QSAR BA = ΣaiXi + μai = contribution of a to BAXi=1 or 0μ = activity of parent skeletonR1 = R2 = R3 = R4If R5 is Cl or CH3and Cl > CH3Then assume Cl always better, regardless of othersubstituents
171Scaffold hoppingFigure 2.30 Example of scaffold hopping to identify new cholesterol-lowering statins from mevastatin
172Scaffold hoppingFigure 2.31 A variation of scaffold hopping that involves disconnection of bonds, rotation or flipping of the core, and reconnection of the pharmacophoric groups
173Computer-Assisted Drug Design Discovery of the influenza drug zanamivir (RelenzaTM) A protein (hemagglutinin) at the surface of a virus binds to sialic acid residues on receptors at the host cell surface.Sialic acidLeadThe virus has another protein (neuraminidase), which is an enzymethat cleaves sialic acid residues from the cell surfaceThe virus enters the cell and replicates in the nucleus.
174Progeny virus particles escape the cell, which no longer has sialic acid residues on its surface to trap the virus.The virus particles spread to other cells.Inhibition of neuraminidase would prevent the releaseand spread of virus particles.
175Random screen identified 2.129 (R = OH) as a weak inhibitor. Crystal structure of influenza A neuraminidase with inhibitor bound was obtained.NH3+ groupComputation (using GRID program) suggested 4-OH should be replaced by 4-NH2, which when protonated would interact with Glu-119 (Fig 2.32).From the crystal structure, extension of 4-ammonium with 4-guanidinium (2.93, zanamivir) would extend binding to Glu-227 as well (Fig. 2.32).groupFigure 2.32 Crystal structure of neuraminidase active site with inhibitors bound. (A) Interaction of the protonated amino group of (R = NH3+) with Glu-119. (B) Interaction of the protonated guanidinium group of with Glu-119 and (red arrow) Glu-227. Adapted with permission from Macmillan Publishers Ltd: Nature (von Itzstein, M., et al. Rational design of potent sialidase-based inhibitors of influence virus replication. Nature 1993, 363, 418–423) Copyright 1993.
176Generally, drug discovery is not this easy - need a cyclic approach. Identify receptor binderObtain crystal structure of receptor with molecule boundDo calculations and dockingSynthesize new compoundsAssayObtain another crystal structure with more potent binderRepeat cycle
177Computer modeling can be used to identify the pharmacophore. By overlaying the structure of the antitumor drug paclitaxel (2.72, Taxol) with those of 4 othernatural products that also stabilize microtubules in competition with paclitaxel,(see next slide)
178a common pharmacophore (Fig. 2.34, next slide) was identified. Figure 2.33 Five natural products found to promote stabilization of microtubules. The boxed sections were used to identify a common pharmacophore. With permission for I. Ojima (1999). Reprinted with permission from Proc. Natl. Acad. Sci. USA 1999, 96, 4256–4261. Copyright 1999 National Academy of Sciences, U.S.A.a common pharmacophore (Fig. 2.34, next slide) was identified.
179A hybrid structure was then constructed (2.130). Figure 2.34 Common pharmacophore based on the composite of boxed sections in Figure With permission for I. Ojima (1999). Reprinted with permission from Proc. Natl. Acad. Sci. USA 1999, 96, 4256–4261. Copyright 1999 National Academy of Sciences, U.S.A.